Literature DB >> 35316551

A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders.

Farnoosh Seirafianpour1, Homa Pourriyahi1, Milad Gholizadeh Mesgarha2, Arash Pour Mohammad1, Zoha Shaka2,3, Azadeh Goodarzi4.   

Abstract

With dermatologic side effects being fairly prevalent following vaccination against COVID-19, and the multitude of studies aiming to report and analyze these adverse events, the need for an extensive investigation on previous studies seemed urgent, in order to provide a thorough body of information about these post-COVID-19 immunization mucocutaneous reactions. To achieve this goal, a comprehensive electronic search was performed through the international databases including Medline (PubMed), Scopus, Cochrane, Web of science, and Google scholar on July 12, 2021, and all articles regarding mucocutaneous manifestations and considerations after COVID-19 vaccine administration were retrieved using the following keywords: COVID-19 vaccine, dermatology considerations and mucocutaneous manifestations. A total of 917 records were retrieved and a final number of 180 articles were included in data extraction. Mild, moderate, severe and potentially life-threatening adverse events have been reported following immunization with COVID vaccines, through case reports, case series, observational studies, randomized clinical trials, and further recommendations and consensus position papers regarding vaccination. In this systematic review, we categorized these results in detail into five elaborate tables, making what we believe to be an extensively informative, unprecedented set of data on this topic. Based on our findings, in the viewpoint of the pros and cons of vaccination, mucocutaneous adverse events were mostly non-significant, self-limiting reactions, and for the more uncommon moderate to severe reactions, guidelines and consensus position papers could be of great importance to provide those at higher risks and those with specific worries of flare-ups or inefficient immunization, with sufficient recommendations to safely schedule their vaccine doses, or avoid vaccination if they have the discussed contra-indications.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  AstraZeneca; AstraZeneca/Oxford; Bharat; COVID-19 vaccine; Comirnaty; Janssen; Johnson & Johnson; Moderna; Pernio; Petechia; Pfizer; Pfizer-BioNTech; SARS-Cov-2; Sinopharm; Sinovac; Sputnik; Vaccine Adverse Event Reporting System; acute; adverse effect; adverse event; adverse event following immunization; allergy; angioedema; atopic dermatitis; collagen vascular disease; cutaneous; cyanosis; delayed; delayed-type hypersensitivity; dermatology; ecchymosis; edema; erythema multiforme; exanthematous rash; herpes; hidradenitis suppurativa; inflammatory bowel disease; injection site reaction; late; local site reaction; maculopapular rash; mastocytosis; morbilliform rash; mucocutaneous; mucosal; pemphigoid; pemphigus; pityriasis rosea; pruritus; psoriasis; purpura; remote site reaction; rheumatic disorders; side effect; urticaria; vaccine; zoster

Mesh:

Substances:

Year:  2022        PMID: 35316551      PMCID: PMC9111423          DOI: 10.1111/dth.15461

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   3.858


  132 in total

1.  Global Recommendations on COVID-19 Vaccines and Soft Tissue Filler Reactions: A Survey-Based Investigation in Cooperation With the International Society for Dermatologic and Aesthetic Surgery (ISDS).

Authors:  Robert H Gotkin; Uliana Gout; Sonja Sattler; Miriam Emily Piansay-Soriano; Rungsima Wanitphakdeedecha; Sahar Ghannam; Elena Rossi; Teresita S Ferrariz; Doris Hexsel; Konstantin Frank; Kristina Davidovic; Deborah S Sarnoff; Sebastian Cotofana
Journal:  J Drugs Dermatol       Date:  2021-04-01       Impact factor: 2.114

2.  COVID-19 Vaccine Reactions in Dermatology: "Filling" in the Gaps.

Authors:  Shauna M Rice; Sarah D Ferree; Arianne S Kourosh
Journal:  Cutis       Date:  2021-06

3.  Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials.

Authors:  Hong-Xing Pan; Jian-Kai Liu; Bao-Ying Huang; Gui-Fan Li; Xian-Yun Chang; Ya-Fei Liu; Wen-Ling Wang; Kai Chu; Jia-Lei Hu; Jing-Xin Li; Dan-Dan Zhu; Jing-Liang Wu; Xiao-Yu Xu; Li Zhang; Meng Wang; Wen-Jie Tan; Wei-Jin Huang; Feng-Cai Zhu
Journal:  Chin Med J (Engl)       Date:  2021-04-28       Impact factor: 2.628

4.  Toward a COVID-19 vaccine strategy for patients with pemphigus on rituximab.

Authors:  Reid A Waldman; Marina Creed; Kelley Sharp; Jonas Adalsteinsson; Jaime Imitola; Timothy Durso; Jun Lu
Journal:  J Am Acad Dermatol       Date:  2020-10-29       Impact factor: 11.527

5.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Authors:  Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks
Journal:  N Engl J Med       Date:  2020-12-30       Impact factor: 91.245

6.  A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine.

Authors:  Haralampos M Moutsopoulos
Journal:  J Autoimmun       Date:  2021-05-01       Impact factor: 7.094

7.  Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.

Authors:  Robert W Frenck; Nicola P Klein; Nicholas Kitchin; Alejandra Gurtman; Judith Absalon; Stephen Lockhart; John L Perez; Emmanuel B Walter; Shelly Senders; Ruth Bailey; Kena A Swanson; Hua Ma; Xia Xu; Kenneth Koury; Warren V Kalina; David Cooper; Timothy Jennings; Donald M Brandon; Stephen J Thomas; Özlem Türeci; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2021-05-27       Impact factor: 91.245

8.  Histopathologic survey on lung necropsy specimens of 15 patients who died from COVID-19: A large study from Iran with a high rate of anthracosis.

Authors:  Siavash Kooranifar; Alireza Sadeghipour; Taghi Riahi; Azadeh Goodarzi; Sanaz Tabrizi; Navid Davoody
Journal:  Med J Islam Repub Iran       Date:  2021-05-17

9.  Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.

Authors:  Cristina Menni; Kerstin Klaser; Anna May; Lorenzo Polidori; Joan Capdevila; Panayiotis Louca; Carole H Sudre; Long H Nguyen; David A Drew; Jordi Merino; Christina Hu; Somesh Selvachandran; Michela Antonelli; Benjamin Murray; Liane S Canas; Erika Molteni; Mark S Graham; Marc Modat; Amit D Joshi; Massimo Mangino; Alexander Hammers; Anna L Goodman; Andrew T Chan; Jonathan Wolf; Claire J Steves; Ana M Valdes; Sebastien Ourselin; Tim D Spector
Journal:  Lancet Infect Dis       Date:  2021-04-27       Impact factor: 25.071

10.  Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: A randomised, double-blind, placebo-controlled, phase I trial.

Authors:  Yuyi Liao; Yuan Li; Rongjuan Pei; Xin Fang; Peiyu Zeng; Renfeng Fan; Zhiqiang Ou; Jinglong Deng; Jian Zhou; Wuxiang Guan; Yuanqin Min; Fei Deng; Hua Peng; Zheng Zhang; Chunyan Feng; Baobao Xin; Jianfeng He; Zhongyu Hu; Jikai Zhang
Journal:  Emerg Microbes Infect       Date:  2021-07-01       Impact factor: 7.163

View more
  6 in total

Review 1.  A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders.

Authors:  Farnoosh Seirafianpour; Homa Pourriyahi; Milad Gholizadeh Mesgarha; Arash Pour Mohammad; Zoha Shaka; Azadeh Goodarzi
Journal:  Dermatol Ther       Date:  2022-04-11       Impact factor: 3.858

2.  Concurrent COVID-19 and pneumocystis carinii pneumonia in a patient subsequently found to have underlying hairy cell leukemia.

Authors:  Vahan Moradians; Bahareh Shateri Amiri; Leyla Bahadorizadeh; Milad Gholizadeh Mesgarha; Shahrzad Sadeghi
Journal:  Radiol Case Rep       Date:  2022-07-02

Review 3.  Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies.

Authors:  Xueyi Huang; Xiaoqian Liang; Jiao Zhang; Hang Su; Yongfeng Chen
Journal:  J Clin Med       Date:  2022-07-08       Impact factor: 4.964

Review 4.  Oral Lesions Following Anti-SARS-CoV-2 Vaccination: A Systematic Review.

Authors:  Federica Di Spirito; Alessandra Amato; Maria Pia Di Palo; Maria Contaldo; Francesco D'Ambrosio; Roberto Lo Giudice; Massimo Amato
Journal:  Int J Environ Res Public Health       Date:  2022-08-17       Impact factor: 4.614

5.  More data on erythema annulare centrifugum induced by COVID-19 vaccination.

Authors:  Alexander Kreuter; Jimmy Jos Puthussery; Julia Hyun; Valentina Laura Müller
Journal:  Dermatol Ther       Date:  2022-06-21       Impact factor: 3.858

6.  Constrictive pericarditis following inactivated virus COVID-19 vaccine: a case report with review of the literature.

Authors:  Shokoufeh Hajsadeghi; Milad Gholizadeh Mesgarha; Elahe Saberi Shahrbabaki; Maryam Pishgahi; Aria Ebadi Fard Azar; Arash Pour Mohammad
Journal:  Radiol Case Rep       Date:  2022-08-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.